News
Dr. Carolina Escobar and Dr. Oscar Bronsther explore the revolutionary world of gene and cell therapy with Spencer on the Self-Funded Podcast. Discover how these innovative treatments offer hope for rare diseases and what it means for healthcare funding. With discussions on CRISPR technology, ethical concerns, and equitable access, this episode sheds light on the […]
Discussing the newly approved sickle cell gene therapy drugs and the current state of gene and cell therapy
Dive into the world of gene and cell therapy with Symphony Benefits Solution and discover how these groundbreaking treatments are revolutionizing healthcare by altering genetic material and transplanting healthy cells to combat various diseases. Learn about the real-life impact on patients, the exciting future prospects of personalized medicine, and the innovative solutions addressing the challenges […]
The recent failure of Pfizer’s late-stage trial for Duchenne muscular dystrophy (DMD) gene therapy marks a significant setback for patients but opens the door for competitors like Sarepta Therapeutics. Pfizer’s gene therapy did not improve motor function in young boys and follows a similar setback for Sarepta’s Elevidys. Despite this, Sarepta remains optimistic, citing positive […]
Breaking News! Pfizer Inc. has just received FDA approval for Beqvez™, a groundbreaking gene therapy for adults with moderate to severe hemophilia B. Beqvez offers a life-changing treatment option for those who currently use factor IX prophylaxis therapy or have experienced serious bleeding episodes and is currently priced at $3.5 million At Symphony Benefits Solution, […]
Symphony Benefits Solution is the industry’s first fullyintegrated solution for high-cost benefits, including Transplant, Cancer,ESRD/Dialysis, and Gene & Cell Therapies into a single program. This informative webinar will discuss: Attendees will have the opportunity to delve into the intricategene and cellular therapy landscape and comprehensively understand the latest developments and trends in this field.
UPDATE: A New FDA approval has been released for Breyanzi. A request was submitted for approval for the expanded indication to include Relapsed and Refractory (R/R) Follicular Lymphoma and Marginal Zone Lymphoma with a PDUFA date of 5/23. Only the Follicular Lymphoma has been approved so far, so we are still anxiously awaiting a decision on […]
Another new FDA approval expanding the indication for Abecma. Previously, it was approved only after failure of 4 or more prior lines of therapy. However, due to showing a progression-free survival benefit 3 times that of standard regimens, it is now approved for use after only 2 lines of previous therapy. Navigating the complexities of […]
Orchard’s recent reveal of Lenmeldy’s $4.25 million price tag has sparked conversations about the affordability of groundbreaking gene therapies. While Lenmeldy stands as the most expensive one-time gene therapy, it’s important to broaden our view beyond headline figures. Lesser-known treatments like Zokinvy and Myalept, which are administered monthly, quietly accumulate costs that rival or exceed […]
